- Home
- SSTK vs BCYC Comparison
SSTK vs BCYC Comparison
Compare SSTK & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTK
- BCYC
- Stock Information
- Founded
- SSTK 2003
- BCYC 2009
- Country
- SSTK United States
- BCYC United Kingdom
- Employees
- SSTK N/A
- BCYC N/A
- Industry
- SSTK EDP Services
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- SSTK Technology
- BCYC Health Care
- Exchange
- SSTK Nasdaq
- BCYC Nasdaq
- Market Cap
- SSTK 668.4M
- BCYC 566.5M
- IPO Year
- SSTK 2012
- BCYC 2019
- Fundamental
- Price
- SSTK $18.70
- BCYC $7.99
- Analyst Decision
- SSTK Buy
- BCYC Buy
- Analyst Count
- SSTK 4
- BCYC 11
- Target Price
- SSTK $43.67
- BCYC $25.00
- AVG Volume (30 Days)
- SSTK 282.5K
- BCYC 273.0K
- Earning Date
- SSTK 07-29-2025
- BCYC 08-12-2025
- Dividend Yield
- SSTK 7.08%
- BCYC N/A
- EPS Growth
- SSTK 38.48
- BCYC N/A
- EPS
- SSTK 1.81
- BCYC N/A
- Revenue
- SSTK $1,010,504,000.00
- BCYC $25,722,000.00
- Revenue This Year
- SSTK $10.45
- BCYC $7.35
- Revenue Next Year
- SSTK $3.19
- BCYC N/A
- P/E Ratio
- SSTK $10.28
- BCYC N/A
- Revenue Growth
- SSTK 14.20
- BCYC N/A
- 52 Week Low
- SSTK $14.35
- BCYC $6.10
- 52 Week High
- SSTK $44.45
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- SSTK 45.91
- BCYC 46.46
- Support Level
- SSTK $19.57
- BCYC $8.40
- Resistance Level
- SSTK $21.29
- BCYC $8.88
- Average True Range (ATR)
- SSTK 0.83
- BCYC 0.50
- MACD
- SSTK -0.06
- BCYC -0.00
- Stochastic Oscillator
- SSTK 23.60
- BCYC 24.40
About SSTK Shutterstock Inc.
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.